The Role of Lebrikizumab in the Treatment of Atopic Dermatitis in the Adult Population

Division

West Florida

Hospital

Largo Medical Center

Document Type

Manuscript

Publication Date

7-4-2023

Keywords

IL-13, atopic dermatitis, biologics, eczema, immunosuppressants, management

Disciplines

Dermatology | Skin and Connective Tissue Diseases

Abstract

Although there are many atopic dermatitis (AD) treatments, finding a long-term medication with minimal side effects can be difficult. This review characterizes lebrikizumab as AD treatment in adults. A literature search was conducted to examine lebrikizumab's role in treating moderate to severe AD. In a phase III trial, 74% of adults with AD treated with lebrikizumab 250 mg every 4 weeks achieved an Investigator Global Assessment of 0/1, 79% achieved Eczema Area and Severity Index 75 and 79% experienced improvements in pruritus numeric rating scale scores relative to placebo. Common adverse effects in the ADvocate1 and ADvocate2 trials were conjunctivitis (7 and 8%, respectively), nasopharyngitis (4 and 5%, respectively) and headache (3 and 5%, respectively). Results from clinical trials suggest that lebrikizumab may be a viable alternative for AD management.

Publisher or Conference

Immunotherapy

Link to Full Text

Share

COinS